3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Primary Myelofibrosis
28
Myeloproliferative Disorders
21
Polycythemia Vera
16
Thrombocythemia, Essential
7
Neoplasms
7
Pancreatic Neoplasms
6
Multiple Myeloma
6
Leukemia
6
Hematologic Diseases
5
Myelodysplastic Syndromes
4
Graft vs Host Disease
4
Colorectal Neoplasms
4
Bone Marrow Diseases
4
Thrombocytosis
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Follicular
3
Leukemia, Myeloid, Acute
3
Carcinoma, Non-Small-Cell Lung
3
Bronchiolitis Obliterans Syndrome
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Lymphoma
2
Uveal Melanoma
1
Thalassemia
1
Recurrence
1
Preleukemia
1
Precancerous Conditions
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Neoplasms by Histologic Type
1
Interventions
sargramostim
2
Monatide (IMS 3015)
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Azacitidine
2
venetoclax
1
ruxolitinib
1
rucaparib
1
olaparib
1
cc-486
1
Pemetrexed
1
Observation
1
Nivolumab
1
Decitabine
1
Cytarabine
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Pathologic Complete Response
×
ruxolitinib
×
Clear all
NCT04934670
2024-08-27
2002
Xenikos
Phase 3
Terminated
12 enrolled
12 charts